Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 20/20 | 0.52 |
| ▸ | DDB1 | Q16531 | 4/20 | 0.51 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.49 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26048893 | 0.92 | CRBN (0.54) | CRBNDDB1IKZF3BRD4 | |
| SCHEMBL26042981 | 0.90 | CRBN (0.41) | CRBNDDB1IKZF3 | |
| SCHEMBL24207833 | 0.86 | CRBN (0.57) | CRBNDDB1IKZF3BRD4 | |
| SCHEMBL26048892 | 0.83 | CRBN (0.52) | CRBNDDB1IKZF3BRD4 | |
| SCHEMBL26042986 | 0.81 | CRBN (0.43) | CRBNDDB1IKZF3BRD4 | |
| SCHEMBL5740168 | 0.81 | CRBN (0.67) | CRBNDDB1IKZF3BRD4 | |
| SCHEMBL23594202 | 0.80 | CRBN (0.73) | CRBNDDB1IKZF3 | |
| SCHEMBL24207113 | 0.79 | CRBN (0.60) | CRBNDDB1IKZF3BRD4 | |
| SCHEMBL22158590 | 0.79 | CRBN (0.71) | CRBNDDB1IKZF3 | |
| SCHEMBL24966246 | 0.77 | CRBN (0.69) | CRBNDDB1IKZF3BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | EGFR, CBL, ERBB2 | CRBN 144/4885DDB1 438/4885IKZF3 999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.